Trial reportWorld journal of gastroenterology2008
Impact of alanyl-glutamine dipeptide on severe acute pancreatitis in early stage.
Trial report in World journal of gastroenterology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 3 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Antioxidant therapy in acute, chronic and post-endoscopic retrograde cholangiopancreatography pancreatitis: An updated systematic review and meta-analysis.World journal of gastroenterology · 2015Pooled it
- Glutamine supplementation for critically ill adults.The Cochrane database of systematic reviews · 2014Pooled it
- Antioxidant therapy in the management of acute, chronic and post-ERCP pancreatitis: a systematic review.World journal of gastroenterology · 2009Pooled it
- Efficacy of enteral glutamine supplementation in patients with severe and predicted severe acute pancreatitis- A randomized controlled trial.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2019Trial
- The effect of Chaiqin Chengqi Decoction () on modulating serum matrix metalloproteinase 9 in patients with severe acute pancreatitis.Chinese journal of integrative medicine · 2013Trial
- Translational Pharmaco-Nutritional Approaches in the Management of Clinical Acute Pancreatitis-A Narrative Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Targeting Oxidative Stress in Acute Pancreatitis: A Critical Review of Antioxidant Strategies.Nutrients · 2025Review
- Precision nutrition management in hyperlipidemia-associated acute pancreatitis: mechanistic insights and personalized therapeutic approaches.Frontiers in nutrition · 2025Review
- Review
- Antioxidant Therapy in Pancreatitis.Antioxidants (Basel, Switzerland) · 2021Review
- Glutamine Supplementation Enhances the Effects of a Low FODMAP Diet in Irritable Bowel Syndrome Management.Frontiers in nutrition · 2021Article
- Recent Advances on Nutrition in Treatment of Acute Pancreatitis.Frontiers in immunology · 2017Review
- Drug Therapy for Acute Pancreatitis.Current treatment options in gastroenterology · 2015Article
- Pharmacologic therapy for acute pancreatitis.World journal of gastroenterology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo evaluate the therapeutic effect of alanyl-glutamine dipeptide (AGD) in the treatment of severe acute pancreatitis (SAP) in early and advanced stage.
methodsEighty patients with SAP were randomized and received 100 mL/d of 20% AGD intravenously for 10 d starting either on the day of (early treatment group) or 5 d after (late treatment group) admission. Groups had similar demographics, underlying diseases, Ranson score, Acute Physiology and Chronic Health Evaluation II (APACHE II) score, and Balthazar's computed tomography (CT) score at the beginning of the study and underwent similar other medical and nutritional management.
resultsThe duration of acute respiratory distress syndrome (2.7 +/- 3.3 d vs 12.7 +/- 21.0 d, P < 0.01), renal failure (1.3 +/- 0.5 d vs 5.3 +/- 7.3 d, P < 0.01), acute hepatitis (3.2 +/- 2.3 d vs 7.0 +/- 7.1 d, P < 0.01), shock (1.7 +/- 0.4 d vs 4.8 +/- 3.1 d, P < 0.05), encephalopathy (2.3 +/- 1.9 d vs 9.5 +/- 11.0 d, P < 0.01) and enteroparalysis (2.2 +/- 1.4 d vs 3.5 +/- 2.2 d, P < 0.01) and hospital stay (28.8 +/- 9.4 d vs 45.2 +/- 27.1 d, P < 0.01) were shorter in the early treatment group than in the late treatment group. The 15-d APACHE II score was lower in the early treatment group than in the late treatment group (5.0 +/- 2.4 vs 8.6 +/- 3.6, P < 0.01). The infection rate (7.9% vs 26.3%, P < 0.05), operation rate (13.2% vs 34.2%, P < 0.05) and mortality (5.3% vs 21.1%, P < 0.05) in the early treatment group were lower than in the late treatment group.
conclusionEarly treatment with AGD achieved a better clinical outcome in SAP patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.